Can diabetes drugs shrink dangerous heart fat to prevent future attacks?
NCT ID NCT07297589
Summary
This study is testing if two common diabetes drugs, dapagliflozin and semaglutide, can reduce a specific type of fat around the heart (epicardial fat) in people who have just had a serious heart attack. Researchers believe lowering this fat may help prevent future heart problems. Over 12 months, they will measure changes in heart fat and track patients' health outcomes to see which drug works better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEMI - ST ELEVATION MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Unidad Medica de Alta Especialidad No. 1, Bajío
RECRUITINGLeón, Guanajuato, 37260,, Mexico
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.